Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Glycotest
Merion Station, Pennsylvania, United Statesglycotest.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Glycotest’s lead HCC Panel blood test for early-stage hepatocellular carcinoma has significantly outperformed the current standard blood test in multiple preliminary clinical studies. The technology is designed to detect curable early-stage liver cancer and other serious liver diseases using non-invasive blood samples by measuring abnormal fucosylation of serum glycoproteins[1][3][4].
- Therapeutic areas
- OncologyGastroenterology
- Modalities
- Diagnostic testDevice (blood-based diagnostic assay)
- Industry
- Protein Biomarker Diagnostics
02
Partnerships
University of Georgia for accelerating novel liver cancer diagnostic assays[4]
Beyond the preview
Go deeper on Glycotest.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Glycotest.